Walleye Capital
NBIX icon

Walleye Capital’s Neurocrine Biosciences NBIX Stock Holding History

Walleye Capital’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,200
Closed -$170K – 4764
2025
Q4 		$170K Buy
+1,200
New +$174K ﹤0.01% 3624
2024
Q4 		– Sell
-200
Closed -$23K – 5302
2024
Q3 		$23K Sell
200
-5,900
-97% -$809K ﹤0.01% 4789
2024
Q2 		$840K Sell
6,100
-18,200
-75% -$2.5M ﹤0.01% 3027
2024
Q1 		$3.35M Buy
+24,300
New +$3.32M 0.01% 1601
2020
Q2 		– Sell
-2,400
Closed -$208K – 844
2020
Q1 		$208K Sell
2,400
-15,800
-87% -$1.55M 0.05% 432
2019
Q4 		$1.96M Sell
18,200
-22,800
-56% -$2.39M 0.13% 204
2019
Q3 		$3.69M Buy
41,000
+1,200
+3% +$112K 0.22% 86
2019
Q2 		$3.36M Buy
39,800
+17,800
+81% +$1.46M 0.37% 30
2019
Q1 		$1.94M Buy
+22,000
New +$1.84M 0.32% 40

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Walleye Capital's NBIX Position: Q1 2026 in Review

Walleye Capital sold out of Neurocrine Biosciences (NBIX) in Q1 2026, closing a stake of 90,325 shares — an estimated $12.8M sold.

Walleye Capital first reported a position in NBIX in Q3 2019 and held it in 17 quarters. The position peaked at $12.8M in Q4 2025. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

  • Walleye Capital reported no remaining Neurocrine Biosciences position as of Q1 2026 after selling out during the quarter.
  • Walleye Capital sold 90,325 Neurocrine Biosciences shares in Q1 2026, an estimated $12.8M.
  • Walleye Capital first reported a position in Neurocrine Biosciences in Q3 2019 and held it in 17 quarters.
  • Walleye Capital's Neurocrine Biosciences position peaked at $12.8M in Q4 2025.
  • 694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on Walleye Capital's 13F filing for Q1 2026, filed 11 May 2026.